NVZMF (Novonesis (Novozymes) B) Interest Expense : $-86 Mil (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novonesis (Novozymes) B's interest expense for the three months ended in Mar. 2025 was $ -21 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-86 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novonesis (Novozymes) B's Operating Income for the three months ended in Mar. 2025 was $ 298 Mil. Novonesis (Novozymes) B's Interest Expense for the three months ended in Mar. 2025 was $ -21 Mil. Novonesis (Novozymes) B's Interest Coverage for the quarter that ended in Mar. 2025 was 14.28. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novonesis (Novozymes) B Interest Expense Historical Data

The historical data trend for Novonesis (Novozymes) B's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Interest Expense Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-10.30

-15.50

-14.50

-25.19

-80.00

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-17.46	-20.54	-26.37	-38.74	-20.87

Novonesis (Novozymes) B Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86 Mil.

Novonesis (Novozymes) B (OTCPK:NVZMF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novonesis (Novozymes) B's Interest Expense for the three months ended in Mar. 2025 was $-21 Mil. Its Operating Income for the three months ended in Mar. 2025 was $298 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $1,372 Mil.

Novonesis (Novozymes) B's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	298.054	/	-20.865
	=	14.28

The higher the ratio, the stronger the company's financial strength is.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM:Germany NZM:Germany NZM2:Germany NZM2:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.